Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients

Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients

Introduction: The prevalence of Hepatitis C (HCV) in Spain is 2,5%, with a high morbimortality rate. Triple therapy based on telaprevir plus peginterferon/ribavirin ([T/PR]) has demonstrated to be an effective approach in treatment-naïve G1-HCV patients. This analysis evaluated, through a Markov mod...

Full description

Saved in:
Bibliographic Details
Main Authors: Blanca Gros, María Buti, Itziar Oyagüez, Raúl J Andrade, Miguel A. Serra, Juan Turnes, Miguel A. Casado
Format: Article
Language:English
Published: Elsevier 2014-09-01
Series:Farmacia Hospitalaria
Subjects:
Hepatitis C
Telaprevir
; Genotype 1
Cost-effectiveness
Peginterferon alfa 2a
Ribavirine
Online Access:http://www.aulamedica.es/fh/pdf/7640.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items